Robert J. Jones

28.9k total citations · 1 hit paper
258 papers, 8.2k citations indexed

About

Robert J. Jones is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Robert J. Jones has authored 258 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Pulmonary and Respiratory Medicine, 85 papers in Oncology and 61 papers in Molecular Biology. Recurrent topics in Robert J. Jones's work include Prostate Cancer Treatment and Research (84 papers), Renal cell carcinoma treatment (41 papers) and Bladder and Urothelial Cancer Treatments (30 papers). Robert J. Jones is often cited by papers focused on Prostate Cancer Treatment and Research (84 papers), Renal cell carcinoma treatment (41 papers) and Bladder and Urothelial Cancer Treatments (30 papers). Robert J. Jones collaborates with scholars based in United Kingdom, United States and France. Robert J. Jones's co-authors include Johann S. de Bono, Nordine Cheikh, Karim Fizazi, Howard I. Scher, Cora N. Sternberg, Fred Saad, Thian Kheoh, Christopher J. Logothetis, Kim N. and Paul N. Mainwaring and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Robert J. Jones

246 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

2012 1.0k citations Karim Fizazi, Howard I. Scher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Jones United Kingdom	47	3.2k	2.5k	1.8k	1.7k	1.2k	258	8.2k
George Thomas United States	50	3.8k 1.2×	5.8k 2.3×	976 0.5×	2.9k 1.7×	2.5k 2.0×	239	11.8k
Banu Arun United States	52	1.7k 0.5×	3.3k 1.3×	433 0.2×	6.1k 3.5×	3.9k 3.2×	260	11.5k
E. Premkumar Reddy United States	63	1.1k 0.3×	10.4k 4.1×	572 0.3×	4.8k 2.8×	2.1k 1.7×	203	17.2k
Edward P. Gelmann United States	66	3.3k 1.0×	6.4k 2.5×	141 0.1×	3.3k 1.9×	1.9k 1.5×	157	13.3k
Simak Ali United Kingdom	55	1.5k 0.5×	7.3k 2.9×	430 0.2×	4.2k 2.5×	2.3k 1.9×	157	11.8k
Peeyush K. Lala Canada	62	922 0.3×	4.2k 1.6×	142 0.1×	1.9k 1.1×	2.2k 1.7×	213	12.2k
Robert L. Sutherland Australia	78	3.3k 1.0×	10.4k 4.1×	204 0.1×	7.8k 4.5×	3.8k 3.1×	236	19.2k
Robin L. Anderson Australia	52	1.0k 0.3×	4.4k 1.7×	502 0.3×	2.8k 1.7×	1.4k 1.2×	205	9.4k
Marvin L. Meistrich United States	65	679 0.2×	5.7k 2.2×	799 0.4×	713 0.4×	1.1k 0.9×	257	13.1k
Colleen C. Nelson Australia	56	3.1k 1.0×	5.1k 2.0×	322 0.2×	2.2k 1.3×	2.5k 2.1×	197	9.5k

Countries citing papers authored by Robert J. Jones

Since Specialization

Citations

This map shows the geographic impact of Robert J. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Jones more than expected).

Fields of papers citing papers by Robert J. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Jones. The network helps show where Robert J. Jones may publish in the future.

Co-authorship network of co-authors of Robert J. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Jones. A scholar is included among the top collaborators of Robert J. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Jones. Robert J. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sullivan, Michael, Nicole De La Mata, Angela C Webster, et al.. (2024). The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. SHILAP Revista de lepidopterología. 2(1). 57–57.

Linch, Mark, Gianmarco Leone, Yien Ning Sophia Wong, et al.. (2024). Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 5013–5013. 5 indexed citations

Jones, Robert J., Simon J. Crabb, Mark Linch, et al.. (2024). Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. British Journal of Cancer. 130(6). 897–907. 12 indexed citations

Azad, Arun, André P. Fay, Cezary Szczylik, et al.. (2024). 1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study. Annals of Oncology. 35. S987–S988. 1 indexed citations

Schlack, Katrin, et al.. (2023). Treatment (tx) patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe. European Urology Open Science. 57. S152–S153.

Conroy, Samantha, James W.F. Catto, Axel Bex, et al.. (2023). Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019. British Journal of Urology. 132(5). 541–553. 2 indexed citations

Clark, Emma, Holly Fisher, Ruth Wood, et al.. (2023). Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. SHILAP Revista de lepidopterología. 2. 49–49. 4 indexed citations

Rodríguez‐Vida, Alejo, Syed A. Hussain, Carlos Álvarez-Fernández, et al.. (2023). 2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2). Annals of Oncology. 34. S1201–S1202. 4 indexed citations

Bullement, Ash, Simon J. Crabb, Robert J. Jones, et al.. (2023). Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology. 20(8). 459–470.

10.

Matsubara, Nobuaki, Karim Fizazi, Arun Azad, et al.. (2023). 1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status. Annals of Oncology. 34. S977–S978. 3 indexed citations

11.

Mueller, Tanja, Kimberley Kavanagh, Janet Graham, et al.. (2022). Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal. 28(1). 1197562431–1197562431. 2 indexed citations

12.

Wilson, Brooke E., Andrew J. Armstrong, Johann S. de Bono, et al.. (2022). Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer. 170. 296–304. 20 indexed citations

13.

Hussain, Syed A., J.F. Lester, Richard A. Jackson, et al.. (2022). Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 20 indexed citations

14.

Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations

15.

Rouprêt, Morgan, Francis X. Keeley, Cecilia Maria Cracco, et al.. (2019). Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World Journal of Urology. 37(11). 2289–2296. 13 indexed citations

16.

Jung, Helene, Guido Giusti, Harun Fajković, et al.. (2019). Consultation on UTUC, Stockholm 2018: aspects of treatment. World Journal of Urology. 37(11). 2279–2287. 13 indexed citations

17.

Clark, Emma, Holly Fisher, Denise Howel, et al.. (2019). Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open. 9(12). e034708–e034708. 6 indexed citations

18.

Powles, Thomas, Robert Huddart, Tony Elliott, et al.. (2017). Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer. Journal of Clinical Oncology. 35(1). 48–55. 142 indexed citations

19.

Boyd, Kathleen, et al.. (2015). Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open. 5(10). e007925–e007925. 8 indexed citations

20.

Jones, Robert J. & Christopher Twelves. (2002). Pemetrexed: a multitargeted antifolate (ALIMTA™, LY-231514). Expert Review of Anticancer Therapy. 2(1). 13–22. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact